

#### Announcement Summary

Entity name G MEDICAL INNOVATIONS HOLDINGS LIMITED

Announcement Type New announcement

Date of this announcement Friday August 7, 2020

The Proposed issue is: ☑ A placement or other type of issue

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
GMV	ORDINARY FULLY PAID	100,000,000

# Proposed +issue date

Thursday August 13, 2020

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

# 1.1 Name of +Entity

# G MEDICAL INNOVATIONS HOLDINGS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

1.2 Registered Number Type

ARBN

**Registration Number** 

617204743

1.3 ASX issuer code

GMV

# 1.4 The announcement is

Solution New announcement

# 1.5 Date of this announcement

Friday August 7, 2020

## 1.6 The Proposed issue is:

☑ A placement or other type of issue



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 - Are any of the following approvals required for the placement or other type of issue?

- +Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity

🕑 No

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? Securities class Will the proposed issue of this +security include an offer of attaching +securities? ℭNo

Details of +securities proposed to be issued

ASX +security code and description

GMV : ORDINARY FULLY PAID

#### Number of +securities proposed to be issued

100,000,000

Offer price details

In what currency is the cash consideration being paid?

What is the issue price per +security? AUD 0.05000

AUD - Australian Dollar

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? ☑ Yes



Part 7C - Timetable

#### 7C.1 Proposed +issue date

Thursday August 13, 2020

Part 7D - Listing Rule requirements

7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

Thursday July 16, 2020

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?  $\ensuremath{\mathfrak{S}}$  No

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules? ☑ No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?  $\ensuremath{\mathfrak{C}}$  No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?  $\ensuremath{\mathfrak{C}}$  Yes

7E.1a Who is the lead manager/broker?

MST Financial acted as sole lead manager and bookrunner to the placement

7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

6% commission

7E.2 Is the proposed issue to be underwritten?  $\ensuremath{\mathfrak{C}}$  No



7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

#### Part 7F - Further Information

#### 7F.01 The purpose(s) for which the entity is issuing the securities

Funds to be applied to scale up of the Independent Diagnostic Testing Facility (IDTF) operations and the expansion of the sales team in the United States, and to increase manufacturing volumes of the Prizma device and G Medical Patch.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? No

7F.2 Any other information the entity wishes to provide about the proposed issue